In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Houet
-
Bobo-Dioulasso, Houet, Burkina Faso, 01
- Tinto Halidou
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6 - 59 months
- Weight > 5 kg
- Mono-infection with P. falciparum
- Parasitemia of 4,000-200,000 asexual parasites per µl
- Fever: > 37.5 °C or history of fever in the preceding 24 hours
- Haemoglobin > 5.0 g/dl
- Signed informed consent by the parents or guardians
- Parents' or guardians' willingness and ability to comply with the study protocol for the duration of the trial.
Exclusion Criteria:
- Participation in any other clinical trial during the previous 30 days
- Known hypersensitivity to the study drugs
- Severe and/or complicated malaria (cases will be referred to Bobo-Dioulasso University hospital for treatment)
- Danger signs: not able to drink or breast-feed, vomiting (> twice in 24hours), recent history of convulsions (>1 in 24h), unconscious state, unable to sit or stand;
- Known intercurrent illness or any condition which would place the subject at undue risk or interfere with the results of the study.
- Severe malnutrition (weight for height <70% of the median NCHS/WHO reference)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Artemether -lumefantrine
Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
|
Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004.
A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
Other Names:
|
|
EXPERIMENTAL: Artesunate-amodiaquine
Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
|
Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.
It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg;
50mg/135mg; 100mg/270mg)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PCR unadjusted treatment failure (regardless of genotyping).
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PCR adjusted treatment failure
Time Frame: 42 days
|
42 days
|
|
PCR unadjusted treatment failure
Time Frame: 28 days
|
28 days
|
|
PCR adjusted treatment failure
Time Frame: 28 days
|
28 days
|
|
Fever clearance time
Time Frame: day 1, 2, 3
|
day 1, 2, 3
|
|
Asexual parasite clearance time
Time Frame: day 7, 14, 21, 28, 35, 42
|
day 7, 14, 21, 28, 35, 42
|
|
Gametocytaemia (prevalence and density)
Time Frame: Day 7, 14, 21, 28, 35 and 42
|
Day 7, 14, 21, 28, 35 and 42
|
|
Safety profiles of the two treatments
Time Frame: 42 days overall
|
42 days overall
|
|
Parasites in vitro sensitivity to the drugs tested and their relationship with the in vivo results
Time Frame: before treatment and at the day of reccurrente parasitemia
|
before treatment and at the day of reccurrente parasitemia
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Halidou Tinto, PhD, Centre Muraz
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Lumefantrine
- Artemether
- Artesunate
- Artemether, Lumefantrine Drug Combination
- Amodiaquine
Other Study ID Numbers
Other Study ID Numbers
- Malactres-BF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.